Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

Kidney International

Volumn 71, Issue 8, 2007, Pages 771-777

  Huber, S ^a   Bruns, C J ^a   Schmid, G ^a   Hermann, P C ^a   Conrad, C ^a   Niess, H ^a   Huss, R ^b   Graeb, C ^a   Jauch, K W ^a   Heeschen, C ^a   Guba, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Lymphangiogenesis; Lymphangioma; Lymphatic endothelial cells; mTOR; Sirolimus; VEGF C

Indexed keywords

PROTEIN KINASE; PROTEIN KINASE P70S6; RAPAMYCIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; KIDNEY GRAFT REJECTION; LYMPH FLOW; LYMPHANGIOGENESIS; LYMPHANGIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN EDEMA; SKIN FLAP; SKIN INCISION; WOUND HEALING;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; ENDOTHELIUM, LYMPHATIC; IMMUNOSUPPRESSIVE AGENTS; LAMININ; LYMPHANGIOGENESIS; LYMPHANGIOMA; MICE; MICE, INBRED C57BL; PERITONEAL NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASES; PROTEOGLYCANS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 34247279338     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002112     Document Type: Article

References (23)

1. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25: 387-395.
2. Skobe M, Hamberg LM, Hawighorst T et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159: 893-903.
3. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19: 5598-5605.
4. Giessing M, Budde K. Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem? Nephrol Dial Transplant 2003; 18: 448-449.
5. Aboujaoude W, Milgrom ML, Govani MV. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 2004; 77: 1094-1096.
6. Chhajed PN, Dickenmann M, Bubendorf L et al. Patterns of pulmonary complications associated with sirolimus. Respiration 2006; 73: 367-374.
7. Fuchs U, Zittermann A, Berthold HK et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79: 981-983.
8. Mahe E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476-482.
9. Wadei H, Gruber SA, El-Amm JM et al. Sirolimus-induced angioedema. Am J Transplant 2004; 4: 1002-1005.
10. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004; 16: 564-575.
11. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
12. Guba M, Yezhelyev M, Eichhorn ME et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005; 105: 4463-4469.
13. Mancardi S, Stanta G, Dusetti N, Bestagno M et al. Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant. Exp Cell Res 1999; 246: 368-375.
14. Fritsche L, Dragun D, Neumayer HH, Budde K. Impact of cyclosporine on the development of immunosuppressive therapy. Transplant Proc 2004; 36: 130S-134S.
15. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001; 7: 462-468.
16. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
17. Weninger W, Partanen TA, Breiteneder-Geleff S et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-251.
18. Saaristo A, Karkkainen MJ, Alitalo K. Insights into the molecular pathogenesis and targeted treatment of lymphedema. Ann N Y Acad Sci 2002; 979: 94-110.
19. Saaristo A, Tammela T, Timonen J et al. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J 2004; 18: 1707-1709.
20. Passaniti A, Taylor RM, Pili R et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-528.
21. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001; 98: 136-141.
22. Joukov V, Kumar V, Sorsa T et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 1998; 273: 6599-6602.
23. Veikkola T, Jussila L, Makinen T et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-1231.